Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
January 22, 2019 07:00 ET | uniQure Inc.
~ AMT-130 Poised to Become First AAV Gene Therapy to Enter the Clinic for Huntington’s Disease ~ ~ Lead Product Candidate from Company’s Proprietary miQURE™ Gene Silencing Platform   ~ LEXINGTON,...